BIOTECHNOLOGY

The scalable and secure cloud-based platform makes the imaging data easily available to researchers and provides smart tools to maximize collaborative research for the ultimate benefit of patients and donors. By adopting the PathPresenter platform, biorepositories and organizations have a unique opportunity to generate a return on investment for their digital pathology infrastructure.

TG4050, the first individualized therapeutic vaccine based on the myvac platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO viral backbone.

"At ASCO, we are reporting early clinical data for three therapeutic candidates highlighting the breadth of our pipeline, which lays the foundation for our next wave of precision therapy programs to tackle significant medical challenges," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "Together, these presentations reflect how we are developing differentiated, highly selective therapies against promising disease targets, and demonstrate strong execution in advancing potential treatment options for large patient populations, including HR+/HER2- breast cancer and EGFR-mutant lung cancer. The datasets represent a diversity of fundamental value drivers in our clinical portfolio, which create opportunities to substantially expand our patient impact and highlight our ambition to deliver many more transformational medicines to patients in the future."

The company updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 antibody) in previously untreated PD-L1-selected NSCLC without sensitizing mutations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Vibhor Gupta, Founder and Director at Pangaea, said: “We are excited to partner with Mersey Care NHS Foundation Trusts and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC). The application of Pangaea’s product in the context of mental health conditions is critical, for both patients and clinicians, to support preventative health and precision medicine.”

Neogap has now obtained final approval from the European Patent Office for their pioneering approach to multiplying T-cells outside the body using their EpiTCer® technology and the production of tumor-specific T-cells.

Amplo Biotechnology's development of AMP-201 builds upon it's progression of AMP-101, an AAV-DOK7 gene therapy targeting Dok-7 congenital myasthenic syndrome, which Amplo expects to bring to clinical trial in 2024. Upon demonstrating initial safety and efficacy, the company plans to expand into other neuromuscular conditions, leveraging the vast potential of AMP-101 and AMP-201 to significantly enhance the quality of life for the majority of CMS patients.

“Given the unmet medical need for patients with recurrent/metastatic HPV16+ head and neck cancers, we are thrilled to share the preliminary data on HB-200 in combination with pembrolizumab as they show a robust improvement in objective response rate and prolonged tumor control compared to pembrolizumab alone,” said Joern Aldag, Chief Executive Officer at HOOKIPA. “Efficacy, immunogenicity and safety data observed in our HB-200 program to-date support our decision to progress to a pivotal trial of HB-200 in combination with pembrolizumab as 1st-line treatment for these patients. The data also underscore the scalability of our arenaviral platform across a range of cancers.”